Author:
Beymer Matthew R.,Holloway Ian W.,Pulsipher Craig,Landovitz Raphael J.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference90 articles.
1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.
https://doi.org/10.1126/scitranslmed.3004006
.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
https://doi.org/10.1056/NEJMoa1108524
.
3. United States Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States. 2014.
https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf
. Accessed January 26, 2017 2017.
4. • Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, et al. Safety and feasibility of antiretroviral Preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017;171(11):1063–71.
https://doi.org/10.1001/jamapediatrics.2017.2007
. This study was responsible for expanding the TDF/FTC PrEP indication down to include youth (weight of 35 kg or more) by the U.S. Food and Drug Administration.
5. AIDS Vaccine Advocacy Coalition (AVAC). Regulatory status of Truvada for PrEP. 2019.
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献